Serum Antimullerian Hormone Levels Among Epileptic Patients

Not Applicable

Completed

• Conditions: Epilepsy; Reproductive Issues
• Interventions: Diagnostic Test: serum antimullerian hormone

• Registration Number: NCT05066360
• Lead Sponsor: Near East University, Turkey

Brief Summary

The production of AMH starts in granulosa cells before birth and the levels within the serum decreases towards the menapouse. The levels of AMH do not change throughout the menstruation cycle hovewer, it can be affected in cases related to body mass index (BMI), polycyctic ovarian syndrome (PCOS). The lower levels of AMH had been documented after ovarian surgery, radiotheraphy and chemotheraphy. AMH is a member of Transforming Growth Faktor β (TGF- β ) and it has receptors in brain structures including hyppocammpus. It is highly active neurophysiologically and it has a protective effect against N-methyl-D -aspartate related neuronal injury that is demonstrated both in vivo and in vitro studies. As a result, being a neuroactive hormone; AMH may have an effect on seizures within epileptic patients or serum AMH levels may be effected in epileptic patients when compared with healthy ones.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-07-02
• Study First Submitted: 2021-07-02
• Study First Submitted QC: 2021-10-01
• Study First Posted: 2021-10-04
• Primary Completion: 2022-02-20
• Study Completion: 2023-06-20
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-26
• Last Update Posted: 2024-01-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• Healthy and epileptic volunteer females
• Ages between 12-18
• After menarche

Exclusion Criteria

• ovarian surgery,
• history of radiotherapy
• history of chemotherapy,
• before menarche

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
healthy participants	serum antimullerian hormone	epileptic, menstruating females between 12-18 ages
participants with epilepsy	serum antimullerian hormone	healthy, menstruating females between 12-18 ages

Primary Outcome Measures

Name	Time	Method
serum anti-mullerian hormone levels	baseline, at the time of examination	The comparison of serum levels of anti-mullerian hormone between epileptic and healthy groups

Trial Locations

Locations (1)

Near East University Faculty of Medicine; 🇨🇾 Nicosia, Cyprus